Lab to Label X TDD: Building an Evidence-based ‘Acneceutical’ Toolkit

Given the vast array of available over-the-counter (OTC) acne products, consumers are often left to navigate what best suits their skin through trial and error. Dermatologists can and should play a critical role in guiding patients through the ever-expanding landscape of OTC acne products.

The Lab to Label: Bridging Science and Clinical Application in Sunscreen and Cosmeceutical Vehicles conference, hosted by the George Washington School of Medicine’s Department of Dermatology in Washington, DC, brought clinicians, scientists, and industry partners together to share their expertise and explore the science behind everyday products, including those that line the acne care aisles.

Hilary Baldwin, MD, the Medical Director of the Acne Treatment and Research Center in Brooklyn, NY, uses the term “acneceuticals” to describe the broader group of OTC and cosmeceutical products with ingredients focused on acne management.

Dr. Baldwin explained that OTC acne treatment modalities have valuable potential as monotherapy, adjunctive therapy, and maintenance therapy. The accessibility and affordability of these products can help improve adherence to treatment regimens. One study found that 27% of patients seen for acne at an outpatient dermatology clinic did not fill their prescriptions for acne medication.1 Thus, access to effective, readily available acne treatments may help reduce barriers to care, such as the need to fill a prescription and/or the challenges associated with insurance coverage and cost.1,2

For an OTC product to make acne-related claims, specific actives must be included, such as salicylic acid, benzoyl peroxide, sulfur, resorcinol, or adapalene, explained Sofia Gomez Dopazo, a Scientist at Kenvue. Dr. Baldwin proposed several mechanisms through which complementary ingredients in “acneceuticals” may act. Keratolytics, including alpha- and beta-hydroxy acids, can help promote turnover of epidermal cells in the stratum corneum. Ingredients like niacinamide can offer anti-inflammatory and antibacterial properties, while also helping to limit excess sebum production associated with acne.3,4

The underlying pathophysiology of acne is also critical in determining product formulations. Acne is a disorder of skin barrier dysfunction and may be associated with increased transepidermal water loss, decreased ceramide levels, decreased microbial diversity, and increased pH of the skin.5,6 Products used to prevent or treat breakouts must take the importance of barrier repair and maintenance into consideration.

Cleansers and Moisturizers for Acne-prone Skin

Cleansers with pH values within the skin’s physiological range, including syndet or lipid-free liquid cleansers, are suitable for helping to maintain skin barrier protection without acidic or alkaline disruption of its natural pH, Dr. Baldwin said. Patient preference may also factor into formulation development and dermatologist recommendations, as polymeric-based cleansers may be more suitable for oily complexions while hydrating cleansers may be more suitable for dry or irritated skin.

Dr. Baldwin dispelled the common misconception that patients with oily skin do not need to moisturize, by emphasizing that “sebum is not a moisturizer.” Given the association between acne and transepidermal water loss, it is important that patients with acne and oily-prone skin use moisturizers containing quality ingredients, such as humectants and occlusives for hydration and water retention, along with emollients for soothing the skin.

From Lab to Label Takeaway

OTC “acneceuticals” offer a broad variety of treatment options that may circumvent barriers posed by prescription-only alternatives. Dermatologists should familiarize themselves with the ingredients in OTC acne products and understand why these ingredients were deliberately selected to achieve a desired outcome. To better help navigate the acne care aisle, dermatologists should build an acne toolkit with specific name-brand recommendations.

REFERENCES:

  1. Anderson KL, Dothard EH, Huang KE, Feldman SR. Frequency of primary nonadherence to acne treatment. JAMA Dermatol. 2015;151(6):623–626. https://doi.org/10.1001/jamadermatol.2014.5254
  2. Rubin CB, Lipoff JB. Primary nonadherence in acne treatment: The importance of cost consciousness. JAMA Dermatol. 2015;151(10):1144–1145. https://doi.org/10.1001/jamadermatol.2015.1743
  3. Baldwin H, Bui H, Callender V, et al. The use of acneceuticals to improve acne care: Introduction of a new term and review of the literature. J Drugs Dermatol. 2025;24(3):281–288. https://doi.org/10.36849/JDD.8817
  4. Baldwin H, Frey C, Hebert A, Lain E, Schlesinger T. An algorithm integrating acneceuticals into the management of acne vulgaris. J Drugs Dermatol. 2025;24(4):376–380. https://doi.org/10.36849/JDD.8887
  5. Yamamoto A, Takenouchi K, Ito M. Impaired water barrier function in acne vulgaris. Arch Dermatol Res. 1995;287(2):214–218. https://doi.org/10.1007/BF01262335
  6. Zhou L, Liu X, Li X, He X, Xiong X, Lai J. Epidermal barrier integrity is associated with both skin microbiome diversity and composition in patients with acne vulgaris. Clin Cosmet Investig Dermatol. 2022;15:2065–2075. https://doi.org/10.2147/CCID.S377759

ABOUT THE AUTHORS:

Ariana Zarghami, BA, and Amreen Khakh, MS, are research fellows in the Department of Dermatology at The George Washington University in Washington, DC.